Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCI-H1299 |
Human lung carcinoma cell line | ATCC CRL-5803 | Human | respiratory system | cell line | adherent | siRNA | RNA-Interference | Metafectene SI | publication | A. Margiotta et al., Biochim. et Biophys. Acta, 2017, 1864: 367-381; doi.org/10.1016/j.bbamcr.2016.11.020 | ||
NCI-H295R |
Human adrenal gland carcinoma cell line | ATCC CRL-2128 | Human | other | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | T. Sugawara et al., J. Biol. Chem., Oct 2003; 278: 42487 - 42494 | Link | |
NCI-H295R |
Human adrenocortical carcinoma cell line | ATCC CRL-2128 | Human | other | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | T. Bozoglu, Dissertation, 2016, Ludwig-Maximilians-Universität zu München | Link | |
NCI-H295R |
Human adrenocortical carcinoma cell line | ATCC CRL-2128 | Human | other | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | T. Sugawara et al., J. Endocrinol., Oct 2006; 191: 327 - 337 | Link | |
NCI-H441 |
Human lung papillary adenocarcinoma cell line | ATCC HTB-174 | Human | respiratory system | cell line | adherent | siRNA | RNA-Interference | Metafectene SI | publication | S. M. Usmani et al., Cell. Microbiology, 2012, 14(3): 299–315, doi:10.1111/j.1462-5822.2011.01724.x | Link | |
NCI-H441-eGFP |
Human lung papillary adenocarcinoma cell line, stably expressing eGFP (derivat of NCI-H441) | Human | respiratory system | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | P. del Pino et al., Nano Lett, Oct 2010; 10(10): 3914-21 | |||
NCI-H460 |
Human large cell lung carcinoma cell line | ATCC HTB-177 | Human | respiratory system | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | M.-J. Kim et al., Cancer Letters, 2013, 339: 15–24, doi.org/10.1016/j.canlet.2013.07.027 | Link | |
NHF |
Human neonatal foreskin fibroblasts | Human | genital tract | unknown | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | J. R. Skaar et al., J. Cell Biol., Oct 2009; 187: 25 - 32 | Link | ||
OCM-1 |
Human uveal melanoma cell line | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | M. Venza et al., Biochem. and Biophys. Res. Commun., 2013, 441: 743–750, doi.org/10.1016/j.bbrc.2013.10.114 | |||
OCM-1 |
Human uveal melanoma cell line | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | I. Venza et al., Int. Immunopharmacol., 2014, 21: 439–446; doi.org/10.1016/j.intimp.2014.05.024 | |||
OCM-3 |
Human uveal melanoma cell line | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | M. Venza et al., Biochem. and Biophys. Res. Commun., 2013, 441: 743–750, doi.org/10.1016/j.bbrc.2013.10.114 | |||
OCM-3 |
Human uveal melanoma cell line | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | I. Venza et al., Int. Immunopharmacol., 2014, 21: 439–446; doi.org/10.1016/j.intimp.2014.05.024 | |||
Omm2.5 |
Human uveal melanoma cell line | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | M. Venza et al., Biochem. and Biophys. Res. Commun., 2013, 441: 743–750, doi.org/10.1016/j.bbrc.2013.10.114 | |||
P skin fibroblasts |
Human immortalized skin fibroblasts (patient derived) | Human | skin | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | C. Benincá et al., J. Med. Genet., 2021, 58: 155–167, doi:10.1136/jmedgenet-2020-106861 | Link | ||
Panc-1 |
Human exocrine pancreas carcinoma cells | ATCC CRL-1469 | Human | digestive organs | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | X. Wu et al., PNAS, Nov 2016, 113: E6965 - E6973 | ||
Panc-1 |
Human exocrine pancreas carcinoma cells | ATCC CRL-1469 | Human | digestive organs | cell line | adherent | siRNA | RNA-Interference | Metafectene SI | publication | S. Cogoi et al., Nucleic Acids Res., Apr 2013; 41: 4049 - 4064 | Link | |
Panc-1 |
Human exocrine pancreas carcinoma cells | ATCC CRL-1469 | Human | digestive organs | cell line | adherent | siRNA | RNA-Interference | Metafectene SI | publication | A. D. Konitsiotis et al., PLoS ONE, 2014, 9(3): e89899, doi:10.1371/journal.pone.0089899 | Link | |
PBMC |
Human CD8+ T cells isolated from peripheral blood mononuclear cells | Human | immune system | unknown | siRNA | RNA-Interference | Metafectene PRO | application note | ![]() |
||||
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | U. Weirauch et al., Nucleic Acid Therapeutics, 2013, 23 (4): 264-272, DOI: 10.1089/nat.2012.0407 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene SI | publication | M. B. Morelli et al., BMC Cancer, 2014, 14:921, doi:10.1186/1471-2407-14-921 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | S. Steinmann et al., J. Biol. Chem., Vol. 288, No. 31, pp. 22257–22269, August 2, 2013 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | E. Werwein et al., Nucleic Acids Res., 2019, 47(1): 103–121, doi: 10.1093/nar/gky935 | Link | |
PC-3 |
Human prostate cancer cell line | ATCC CRL-1435 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | application note | ![]() |
||
pHDF |
Human primary dermal fibroblasts | Human | skin | primary cell | adherent | siRNA | RNA-Interference | K2 Transfection System | application note | ![]() |
|||
pHDF |
Human primary dermal fibroblasts | Human | skin | primary cell | adherent | siRNA | RNA-Interference | K2 Transfection System | publication | E. A. Ostrakhovitch et al., PLoS ONE, 2020, 15(11): e0241685, doi.org/10.1371/journal.pone.0241685 | Link |